SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is seeing intense volatility as traders debate its valuation and near-term prospects, especially given the CEO's past stock sales. Community chatter revolves around whether the stock is overextended, with bears anticipating a significant pullback and bulls defending its long-term potential in the quantum computing sector. Discussions also include potential impacts from upcoming earnings and options expirations.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

PRAX is trending as traders weigh recent price action against news of new price targets and a potential offering. The community is actively discussing entry and exit points, with some eyeing shorting opportunities while others remain bullish. Discussions also revolve around the company's trial results and future potential.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community debates recent price action and potential market direction, with discussions ranging from bullish predictions to bearish concerns about a possible cycle top. Community members are actively discussing potential manipulation, the influence of external factors like Trump's policies, and comparing Bitcoin's performance against traditional assets like gold. The conversation also includes speculation about institutional accumulation and the impact of potential regulatory changes on the crypto market.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending as gold prices surge to record highs, fueled by safe-haven demand amid economic uncertainty and renewed trade tensions. The community is discussing the potential for further gains, the possibility of a pullback, and whether gold is becoming overbought. Some investors are rotating into gold as a hedge against a weakening dollar and potential market instability.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending as investors discuss the company's long-term financial targets, specifically its goal of $60B+ in revenue by FY2030, and its expanded AI ecosystem with Google. The community is weighing the potential of new AI integrations like Agentforce 360 and Gemini, and debating if Salesforce is positioned to capture a larger share of the enterprise AI market. Some analysts are reiterating strong buy ratings, citing an attractive valuation relative to free cash flow despite concerns over growth.

Above Food Ingredients, Inc. engages in operating its subsidiaries, Bite Acquisition Corp. (Bite) and Above Food Corp. (Above Food). The Bite is a blank check company that affects a merger, stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Above Food is an ingredient company that provides food products and brands. The company was founded by Lionel Kambeitz on April 18, 2023 and is headquartered in Regina, Canada.

Above Food Ingredients Inc.

ABVE is trending as the stock price experiences volatility, leading to active discussions around short squeezes and potential news catalysts. Community members are debating potential price targets and the impact of options listing, while also highlighting the company's connection to tokenization and gold-backed assets. Some traders express frustration with price manipulation and delayed filings, while others remain confident in the long-term potential.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is trending as investors discuss its potential driven by possible government contracts and tech partnerships, with some believing short covering is contributing to the upward momentum. Community members are actively debating the company's valuation and future prospects within the quantum computing sector, with discussions around potential dilution and management strategies. Despite concerns, bullish sentiment persists, fueled by Roth Capital's raised price target and D-Wave's claimed quantum supremacy.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is trending as it surpassed the $100 mark, triggering excitement among long-term investors who have held the stock since its SPAC days, while also attracting short-sellers betting against its parabolic gains and meme stock status. The community is actively debating whether this is a sustainable breakout or a short-lived bubble, especially given the company's lack of current earnings and sensitivity to potential launch failures. Discussions also revolve around upcoming catalysts like the ISRO launch and potential government contracts, and their impact on the stock's future trajectory.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ is trending as investors discuss its potential in quantum-resistant bitcoin and cybersecurity, with some suggesting a possible short squeeze. Community members are highlighting BTQ's unique approach to building a vertically integrated quantum security stack. The stock's recent movements and potential for significant gains are also driving interest.

Earlyworks Co., Ltd. engages in providing blockchain-based technology solutions. It operates its proprietary private blockchain technology, Grid Ledger System (GLS), a hybrid blockchain that combines the technical advantages of blockchain technology and database technology, to leverage blockchain technology in various applications in a range of industries. It offers software and system development services and consulting and solution services. The company was founded by Satoshi Kobayashi and Hiroki Yamamoto on May 1, 2018 and is headquartered in Tokyo, Japan.

Earlyworks Co Ltd - ADR

ELWS is trending due to its low float and recent volatility, with traders actively discussing potential price targets and halt-ups. Community members are also speculating on the impact of blockchain developments and potential partnerships in the Japanese market. Some traders are watching for breakout opportunities and potential short squeezes.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength?

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TG Therapeutics, Inc. (TGTX) on Wednesday stated that its board of directors has authorized a new share repurchase program to acquire up to an additional $100 million of the company’s common stock.The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024. Under the previous program, TG Therapeutics repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share. CEO Michael S. Weiss <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase">said</a> that the company repurchased $78 million of the stock in August alone at “highly attractive prices.”TGTX stock gained nearly 2% in Wednesday’s pre-market.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TGTX">TGTX stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘low’ levels.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase">said</a> on Wednesday that repurchases under the new program may be made on a time-to-time basis through open market purchases, privately negotiated transactions, or other means.Weiss said that the new repurchase program reflects the company’s conviction that “current market prices do not adequately reflect the multibillion-dollar potential of Briumvi or the long-term growth prospects of TG Therapeutics.”Briumvi is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults. Multiple Sclerosis is a chronic, often disabling, autoimmune disease that affects the brain and spinal cord, disrupting communication between the brain and other parts of the body. The disease symptoms include difficulty walking, blurred vision, and altered sensations in limbs or face.In the <a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-stock-tumbles-after-disappointing-q2-but-company-reaffirms-confidence-in-multiple-sclerosis-drug/chrXrTDRdcR">second quarter</a>, Briumvi’s net product revenue totaled $138.8 million, representing 91% growth over the same period last year and accounting for over 98% of the company’s total revenue.TGTX stock is down 1% this year but up approximately 31% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tectonic-stock-soars-pre-market-after-tuesday-sell-off/chwTUeNRd8m">Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

 TG Therapeutics Board Authorizes New $100M Share Repurchase Program

The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024.

Equity

The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024.


TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line

TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.

 Company News for Aug 5, 2025

TG Therapeutics, Inc. (TGTX) on Monday reaffirmed confidence in its flagship drug Briumvi despite a disappointing second-quarter earnings report.Briumvi is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults. Multiple Sclerosis is a chronic, often disabling, autoimmune disease that affects the brain and spinal cord, disrupting communication between the brain and other parts of the body. The disease symptoms include difficulty walking, blurred vision, and altered sensations in limbs or face.“With multiple growth drivers in place, expanding patient and prescriber bases, increasing brand recognition and the momentum of our media investments, we believe Briumvi is on track to become a multibillion-dollar brand in relapsing MS,” said Adam Waldman, Chief Commercial Officer at TG Therapeutics, on the company’s earnings call while adding that it expects stronger growth from the third quarter (Q3) to the fourth quarter (Q4).The firm also raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million. TG Therapeutics is also evaluating Briumvi in the treatment of Myasthenia Gravis and testing subcutaneous Briumvi, allowing self-administration of the drug.The company now sees a total global revenue target of approximately $585 million for the full year 2025, up from its previous guidance of $575 million.&nbsp;On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TGTX">TGTX</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:1336/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_04_at_1_21_31_PM_png_bda23ffe5e.webp" alt="TGTX's Sentiment Meter and Message Volume as of 1:20 p.m. ET on Aug. 4, 2025 | Source: Stocktwits" width="1336" height="132"><figcaption>TGTX's Sentiment Meter and Message Volume as of 1:20 p.m. ET on Aug. 4, 2025 | Source: Stocktwits</figcaption></figure>TGTX stock slid over 16% on Monday following the downbeat earnings. A Stocktwits user believes the drop in stock following the earnings report is an opportunity to buy more.<stembedurl>https://stocktwits.com/Firstcall/message/623650797</stembedurl>Another opined that the drop is not justifiable, given that the company raised its guidance.<stembedurl>https://stocktwits.com/Firstcall/message/623647493</stembedurl>For the second quarter, the company’s total revenue came in at $141.15 million, compared to $73.47 million in the corresponding quarter of 2024, and below an analyst estimate of $147.76 million. Briumvi’s net product revenue alone came in at $138.8 million, representing 91% growth over the same period last year, and accounting for over 98% of the company’s total revenue.Diluted earnings per share came in at $0.17, above the $0.04 reported in Q2 2024, but below an analyst estimate of $0.25.&nbsp;TGTX stock is down by 3% this year but up by 70% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-rivian-to-report-q2-earnings-tomorrow/chrXpf7RdTz">Lucid, Rivian To Report Q2 Earnings Tomorrow: Retail Watches Warily With Mixed Sentiments</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug

The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million.

TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug

The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million.


TG Therapeutics (TGTX) Misses Q2 Earnings Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and +3.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release

TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in TG Therapeutics Stock?

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$34.47
Prev Close	$35.05
Open	$34.82
Dividend Yield	0.00%
50-Day Moving Average	$31.85
Beta	1.56
Avg. Volume	2.17M
PE Ratio	93.67

52-Week High	$46.48
52-Week Low	$22.61
Market Capitalization	$5.56B
EPS (Annual)	$0.1458
Price to Book	20.04
Revenue Per Employee	$973,384.61
Enterprise Value/EBITDA	N/A

TGTX
TG Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TGTX News

TGTXTG Therapeutics Inc